Opdivo: Additional Ph III ONO-4538-12 data

Additional data from the double-blind, Asian Phase III ONO-4538-12 trial in about 480 patients with unresectable advanced or recurrent gastric cancer refractory to or intolerant of standard

Read the full 279 word article

User Sign In